[
  {
    "ts": "2026-01-05T03:10:13+00:00",
    "headline": "Taking Another Look at Amgen (AMGN)’s Valuation After Its Recent Share Price Pullback",
    "summary": "Amgen (AMGN) has been quietly grinding higher over the past year, and that steady move is catching more investor attention. With revenue and earnings both growing, the stock’s recent pullback looks worth a closer look. See our latest analysis for Amgen. At around $327.64, Amgen’s modest recent share price pullback comes after a strong 90 day share price return of 11.4 percent and a one year total shareholder return of 29.5 percent, which suggests momentum is still broadly constructive. If...",
    "url": "https://finance.yahoo.com/news/taking-another-look-amgen-amgn-031013515.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "ec3c930e-e061-31bd-b8aa-12f4deded9b6",
      "content": {
        "id": "ec3c930e-e061-31bd-b8aa-12f4deded9b6",
        "contentType": "STORY",
        "title": "Taking Another Look at Amgen (AMGN)’s Valuation After Its Recent Share Price Pullback",
        "description": "",
        "summary": "Amgen (AMGN) has been quietly grinding higher over the past year, and that steady move is catching more investor attention. With revenue and earnings both growing, the stock’s recent pullback looks worth a closer look. See our latest analysis for Amgen. At around $327.64, Amgen’s modest recent share price pullback comes after a strong 90 day share price return of 11.4 percent and a one year total shareholder return of 29.5 percent, which suggests momentum is still broadly constructive. If...",
        "pubDate": "2026-01-05T03:10:13Z",
        "displayTime": "2026-01-05T03:10:13Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/8ab44b8ef28c7f69299492d5b9c5a46c",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ACuIXYrNeojUXbAJFhnPIg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8ab44b8ef28c7f69299492d5b9c5a46c.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/B7CQJIEa.2c0sQ0XIU66pg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/8ab44b8ef28c7f69299492d5b9c5a46c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/taking-another-look-amgen-amgn-031013515.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/taking-another-look-amgen-amgn-031013515.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-05T04:37:00+00:00",
    "headline": "1 S&P 500 Stock with Exciting Potential and 2 We Question",
    "summary": "While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.",
    "url": "https://finance.yahoo.com/news/1-p-500-stock-exciting-043700733.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "b208ca7e-5d6e-3643-8bc2-0c6b460ae8df",
      "content": {
        "id": "b208ca7e-5d6e-3643-8bc2-0c6b460ae8df",
        "contentType": "STORY",
        "title": "1 S&P 500 Stock with Exciting Potential and 2 We Question",
        "description": "",
        "summary": "While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.",
        "pubDate": "2026-01-05T04:37:00Z",
        "displayTime": "2026-01-05T04:37:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/85fc5540fd7647d2927a8cba48ff7e92",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "AMGN Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cVRDvNeMN6SVWgnyfhcabA--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/85fc5540fd7647d2927a8cba48ff7e92.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/khfuGqTIKrJ0BdS6OOusRA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/85fc5540fd7647d2927a8cba48ff7e92.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/1-p-500-stock-exciting-043700733.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/1-p-500-stock-exciting-043700733.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "TECH"
            },
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "IFF"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-05T12:52:00+00:00",
    "headline": "Beat the Market the Zacks Way: LATAM, General Motors, Amgen in Focus",
    "summary": "LTM, GM and AMGN highlight Zacks' recent stock-picking wins, delivering notable gains across airlines, autos and biotech despite choppy markets.",
    "url": "https://finance.yahoo.com/news/beat-market-zacks-way-latam-125200784.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "caed1ac3-5764-3c9b-924a-b5eac7cf9961",
      "content": {
        "id": "caed1ac3-5764-3c9b-924a-b5eac7cf9961",
        "contentType": "STORY",
        "title": "Beat the Market the Zacks Way: LATAM, General Motors, Amgen in Focus",
        "description": "",
        "summary": "LTM, GM and AMGN highlight Zacks' recent stock-picking wins, delivering notable gains across airlines, autos and biotech despite choppy markets.",
        "pubDate": "2026-01-05T12:52:00Z",
        "displayTime": "2026-01-05T12:52:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/d9909195d38b3d0a5e8f4add2c63c714",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2TQZFLWGkIHQo3h2cDQoEg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/d9909195d38b3d0a5e8f4add2c63c714.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/s2TXsS1_ghMqeA_9wQwi3Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/d9909195d38b3d0a5e8f4add2c63c714.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/beat-market-zacks-way-latam-125200784.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/beat-market-zacks-way-latam-125200784.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "GS"
            },
            {
              "symbol": "LTM"
            },
            {
              "symbol": "TMO"
            },
            {
              "symbol": "KO"
            },
            {
              "symbol": "AEO"
            },
            {
              "symbol": "LC"
            },
            {
              "symbol": "GM"
            },
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "^IXIC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-05T17:00:44+00:00",
    "headline": "Zenas BioPharma, A Top 1% Stock, Quadrupled In 2025. Why It Just Collapsed.",
    "summary": "Zenas BioPharma stock collapsed Monday despite technically succeeding in a Phase 3 study of its treatment for a rare autoimmune disorder.",
    "url": "https://www.investors.com/news/technology/zenas-biopharma-stock-igg4-related-disease-treatment/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "8e10b071-9774-338b-8480-b6782aa8cd24",
      "content": {
        "id": "8e10b071-9774-338b-8480-b6782aa8cd24",
        "contentType": "STORY",
        "title": "Zenas BioPharma, A Top 1% Stock, Quadrupled In 2025. Why It Just Collapsed.",
        "description": "",
        "summary": "Zenas BioPharma stock collapsed Monday despite technically succeeding in a Phase 3 study of its treatment for a rare autoimmune disorder.",
        "pubDate": "2026-01-05T17:00:44Z",
        "displayTime": "2026-01-05T17:00:44Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/8e10b071-9774-338b-8480-b6782aa8cd24/zenas-biopharma-a-top-1-.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/e954c5b8aeb12f3ae9a32ea3ec992c8f",
          "originalWidth": 1065,
          "originalHeight": 600,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_8M36.DfkvFpQQpC7HaKRg--~B/aD02MDA7dz0xMDY1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/e954c5b8aeb12f3ae9a32ea3ec992c8f.cf.webp",
              "width": 1065,
              "height": 600,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/w9IRMeNSW5IkGlfVkdiIXw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/e954c5b8aeb12f3ae9a32ea3ec992c8f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/zenas-biopharma-stock-igg4-related-disease-treatment/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ZBIO"
            },
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-05T11:26:00+00:00",
    "headline": "Zenas shares crash after top drug misses expectations in immune disease study",
    "summary": "While the company’s bispecific medication obexelimab met its objectives in a trial in IgG4-related disease, it didn’t appear to match the effectiveness of a recently approved Amgen drug.",
    "url": "https://www.biopharmadive.com/news/zenas-obexelimab-IgG4-indigo-study-results/808718/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "c833bb5c-23cd-3a3f-a64a-d000ab80724c",
      "content": {
        "id": "c833bb5c-23cd-3a3f-a64a-d000ab80724c",
        "contentType": "STORY",
        "title": "Zenas shares crash after top drug misses expectations in immune disease study",
        "description": "",
        "summary": "While the company’s bispecific medication obexelimab met its objectives in a trial in IgG4-related disease, it didn’t appear to match the effectiveness of a recently approved Amgen drug.",
        "pubDate": "2026-01-05T11:26:00Z",
        "displayTime": "2026-01-05T11:26:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/87d5d20a48c62d3e085b9105b280a212",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Xr4bemZAp6gAtFHrR8Wmaw--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/87d5d20a48c62d3e085b9105b280a212.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cZIkuy3wXF_fhWuVRjbL2A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/87d5d20a48c62d3e085b9105b280a212.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/zenas-obexelimab-IgG4-indigo-study-results/808718/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/zenas-shares-crash-top-drug-112600202.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ZBIO"
            },
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]